Italian society of hematology, italian society of experimental hematology, and italian group for bone marrow transplantation guidelines for the management of indolent, nonfollicular b-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 2, 2015, Pages 75-85

  Tarella, Corrado ^a   Arcaini, Luca ^b   Baldini, Luca ^c   Barosi, Giovanni ^d   Billio, Atto ^e   Marchetti, Monia ^f   Rambaldi, Alessandro ^g   Vitolo, Umberto ^h   Zinzani, Pier Luigi ⁱ   Tura, Sante ⁱ  

^a MAURIZIANO HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Ospedale Civile di Bolzano   (Italy)

^f Ospedale Cardinal Massaia   (Italy)

^g PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^h Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

FDG PET; GRADE; Rituximab

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; FLUDARABINE; RITUXIMAB;

ANTIBIOTIC THERAPY; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CLINICAL PRACTICE; EVIDENCE BASED PRACTICE; HEMATOLOGY; HUMAN; LYMPHOCYTOMA; MARGINAL ZONE LYMPHOMA; MEDICAL SOCIETY; NODAL MARGINAL ZONE LYMPHOMA; PRACTICE GUIDELINE; PROCESS OPTIMIZATION; REVIEW; SPLENIC LYMPHOMA; STANDARDIZATION; STOMACH SURGERY; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; ITALY; LYMPHOMA, B-CELL; PROCEDURES; STANDARDS;

BONE MARROW TRANSPLANTATION; HEMATOLOGY; HUMANS; ITALY; LYMPHOMA, B-CELL; PRACTICE GUIDELINES AS TOPIC;

EID: 84921746572     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.07.002     Document Type: Review

References (77)

1. S.H. Swerdlow, E. Campo, and N.L. Harris World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 IARC Press Lyon
2. L.M. Morton, S.S. Wang, and S.S. Devesa Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 2006 265 276
3. J.O. Armitage, and D.D. Weisenburger New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project J Clin Oncol 16 1998 2780 2795
4. G.H. Guyatt, A.D. Oxman, and G.E. Vist GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BJM 336 2008 924 926
5. J.H. Ferguson The NIH Consensus Development Program: the evolution of guidelines Int J Technol Assess Health Care 12 1996 460 474
6. A.L. Delbecq, A.H. van de Ven, and D.H. Gustafson Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes 1975 Scott, Foresman Glenview, IL
7. S.P. Treon, L. Xu, and G. Yang Somatic mutation in Waldenström's macroglobulinemia N Engl J Med 367 2012 826 833
8. M.E. Juweid, S. Stroobants, and O.S. Hoekstra Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 2007 571 578
9. M. Karam, L. Novak, and J. Cyriac Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas Cancer 107 2006 175 183
10. P. Brice, Y. Bastion, and E. Lepage Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires, Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 15 1997 1110 1117
11. M. Federico, U. Vitolo, and P.L. Zinzani Prognosis of follicular lymphomas: a predictive model based on a retrospective analysis of 987 cases Blood 95 2000 783 789
12. H. Schulz, J.F. Bohlius, and S. Trelle Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis J Natl Cancer Inst 99 2007 706 714
13. M. Herold, A. Haas, and S. Srock Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study J Clin Oncol 25 2007 1986 1992
14. C. Buske, E. Hoster, and M. Dreyling The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) Leukemia 23 2009 153 161
15. E. Orciuolo, G. Buda, and E. Sordi 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma Leuk Res 34 2010 184 189
16. V. Leblond, S. Johnson, and S. Chevret Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma J Clin Oncol 31 2013 301 307
17. M.J. Rummel, N. Niederle, and G. Maschmeyer Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Lancet 381 2013 1203 1210
18. A. Ferrario, A. Pulsoni, and B. Olivero Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation Cancer 118 2012 3954 3961
19. A. Ferrario, F. Merli, and S. Luminari Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL) Ann Hematol 90 2011 323 330
20. R. Weide, S. Feiten, and V. Friesenhahn Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions Leuk Lymphoma 54 2013 1640 1646
21. M. Koenigsmann, W. Knauf, and M. Herold Fludarabine and bendamustine in refractory and relapsed indolent lymphoma - a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO) Leuk Lymphoma 45 2004 1821 1827
22. J.W. Friedberg, J.M. Vose, and F. Zoung The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma Blood 117 2011 2807 2812
23. T.E. Witzig, P.H. Wiernik, and T. Moore Lenalidomide oral monotherapy produces durable response in relapsed or refractory indolent non-Hodgkin lymphoma J Clin Oncol 27 2009 5404 5409
24. M.J. Rummel, U. Kaiser, and C. Balser Bendamustine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas - final results of the randomized phase III study NHL-22003 on behalf of the StiL Blood 116 2010 abstract 856
25. J.V. Melo, U. Hegde, and A. Parreira Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens J Clin Pathol 40 1987 642 651
26. J. Audouin, A. Le Tourneau, and T. Molina Patterns of bone marrow involvement in 58 patients presenting [with] primary splenic marginal zone lymphoma with or without circulating villous lymphocytes Br J Haematol 122 2003 404 412
27. E. Iannitto, A. Ambrosetti, and E. Ammatuna Splenic marginal zone lymphoma with or without villous lymphocytes: hematologic findings and outcomes in a series of 57 patients Cancer 101 2004 2050 2057
28. X. Troussard, F. Valensi, and E. Duchayne Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients Br J Haematol 93 1996 731 736
29. O. Hermine, F. Lefrère, and J.P. Bronowicki Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection N Engl J Med 347 2002 89 99
30. S.P. Mulligan, E. Matutes, C. Dearden, and D. Catovsky Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases Br J Haematol 78 1991 206 209
31. J. Chacon, M. Mollejo, and E. Munoz Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients Blood 100 2002 1648 1654
32. C. Thieblemont, P. Felman, and F. Berger Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients Clin Lymphoma 3 2002 41 47
33. A.J. Olszewski, and J.J. Castillo Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database Cancer 119 2013 629 638
34. A.J. Olszewski, and S. Ali Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma Ann Hematol 93 2014 449 458
35. A.M. Tsimberidou, D. Catovsky, and E. Schlette Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone Cancer 107 2006 125 135
36. A. Marin-Niebla, M. Else, and F. De la Cruz Rituximab, either as single agent or in combination, is superior to other treatments in terms of response rate and progression-free survival (PFS) in patients with splenic marginal zone lymphoma (SMZL) Blood 118 2011 abstract 4986
37. C. Kalpadakis, G.A. Pangalis, and M.K. Angelopoulou Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy Oncologist 18 2013 190 197
38. G. Cervetti, S. Galimberti, and E. Sordi Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL) Ann Oncol 21 2010 851 854
39. P.G. Isaacson, A. Chott, and S. Nakamura Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) S.H. Swerdlow, E. Campo, N.L. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed 2008 IARC Lyon 185 187
40. W. Dickey, B.D. Kenny, and J.B. McConnell Effect of proton pump inhibitors on the detection of Helicobacter pylori in gastric biopsies Aliment Pharmacol Ther 10 1996 289 293
41. M. Eck, A. Greiner, and B. Schmausser Evaluation of Helicobacter pylori in gastric MALT-type lymphoma: differences between histologic and serologic diagnosis Mod Pathol 12 1999 1148 1151
42. H. Liu, H. Ye, and A. Ruskone-Fourmestraux t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication Gastroenterology 122 2002 1286 1294
43. S. Nakamura, H. Ye, and C.M. Bacon Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation Gut 56 2007 1358 1363
44. A. Rohatiner, F. d'Amore, and B. Coiffier Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma Ann Oncol 5 1994 397 400
45. A. Ruskone-Fourmestraux, B. Dragosics, and A. Morgner Paris staging system for primary gastrointestinal lymphomas Gut 52 2003 912 913
46. M. Raderer, F. Vorbeck, and M. Formanek Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma Br J Cancer 83 2000 454 457
47. W. Fischbach, B. Dragosics, and M.E. Kolve-Goebeler Primary gastric B-cell lymphoma: results of a prospective multicenter study. The Germane Austrian Gastrointestinal Lymphoma Study Group Gastroenterology 119 2000 1191 1202
48. P. Koch, A. Probst, and W.E. Berdel Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96) J Clin Oncol 23 2005 7050 7059
49. J.C. Vaillant, A. Ruskone-Fourmestraux, and P. Aegerter Management and long-term results of surgery for localized gastric lymphomas Am J Surg 179 2000 216 222
50. P. Koch, F. del Valle, and W.E. Berdel Primary gastrointestinal non-Hodgkin lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma: results of the prospective German Multicenter Study GIT NHL 01/92 J Clin Oncol 19 2001 3874 3883
51. Y. Kodera, Y. Yamamura, and S. Nakamura The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma Ann Surg 227 1998 45 50
52. S.H. Kuo, L.T. Chen, and M.S. Wu Long term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment Ann Surg 247 2008 265 269
53. C. Vrieling, D. de Jong, and H. Boot Long-term results of stomach-conserving therapy in gastric MALT lymphoma Radiother Oncol 87 2008 405 411
54. W. Fischbach, S. Schramm, and E. Goebeler Outcome and quality of life favour a conservative treatment of patients with primary gastric lymphoma Z Gastroenterol 49 2011 430 435
55. A. Zullo, C. Hassan, and A. Andriani Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis Am J Gastroenterol 104 2009 1932 1937
56. P. Malfertheiner, F. Megraud, and C.A. O'Morain Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report Gut 61 2012 646 664
57. H.S. Park, Y.J. Kim, and W.I. Yang Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma World J Gastroenterol 16 2010 2158 2162
58. B.W. Hancock, W. Qian, and D. Linch Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial Br J Haematol 144 2009 367 375
59. C. Copie-Bergman, P. Gaulard, and A. Lavergne-Slove Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma Gut 52 2003 1656
60. W. Fischbach, M.E. Goebeler-Kolve, and B. Dragosics Long term outcome of patients with gastric marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series Gut 53 2004 34 37
61. N.R. Schechter, C.S. Portlock, and J. Yahalom Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone J Clin Oncol 16 1998 1916 1921
62. R.W. Tsang, M.K. Gospodarowicz, and M. Pintilie Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome J Clin Oncol 21 2003 4157 4164
63. N. Tomita, T. Kodaira, and H. Tachibana Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma Radiother Oncol 90 2009 231 235
64. P. Hammel, C. Haioun, and M.T. Chaumette Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression J Clin Oncol 13 1995 2524 2529
65. M. Levy, C. Copie-Bergman, and C. Gameiro Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy J Clin Oncol 23 2005 5061 5066
66. B. Streubel, H. Ye, and M.Q. Du Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma Oncology 66 2004 476 480
67. L. Vidal, A. Gafter-Gvili, and R. Gurion Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia Cochrane Database Syst Rev 9 2012 CD009045
68. A. Conconi, G. Martinelli, and A. Lopez-Guillermo Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG) Ann Oncol 22 2011 689 695
69. A. Aviles, M.J. Nambo, and N. Neri Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial Med Oncol 22 2005 57 62
70. G. Martinelli, D. Laszlo, and A.J. Ferreri Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy J Clin Oncol 23 2005 1979 1983
71. E. Zucca, A. Conconi, and D. Laszlo Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study J Clin Oncol 31 2013 565 572
72. A. Salar, E. Domingo-Domenech, and C. Estany Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type Cancer 115 2009 5210 5217
73. Aguiar-Bujanda D, Llorca-Mártinez I, Rivero-Vera JC, et al. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone [e-pub ahead of print]. Hematol Oncol http://dx.doi.org/10.1002/hon.2105, accessed: July 8, 2014.
74. A.J. Olszewski, and J.J. Castillo Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database Ann Oncol 5 2013 1352 1359
75. A. Wirth, M. Gospodarowicz, and B.M. Aleman Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study Ann Oncol 24 2013 1344 1351
76. M. Dreyling, C. Thieblemont, and A. Gallamini ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma Ann Oncol 24 2013 857 877
77. NCCN Guidelines, version 1, 2014: Non-Hodgkin's Lymphomas. Available at: http://www.nccn.org/professionals/default.aspx. Accessed: July 8, 2014.